Clinical Trial Detail

NCT ID NCT02949843
Title Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Comprehensive Cancer Center of Wake Forest University
Indications

non-small cell lung carcinoma

Therapies

Nivolumab + Pembrolizumab

Age Groups: adult child senior

Additional content available in CKB BOOST